Ironwood Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Ironwood Pharmaceuticals's estimated annual revenue is currently $413.3M per year.
- Ironwood Pharmaceuticals's estimated revenue per employee is $1,201,453
- Ironwood Pharmaceuticals's total funding is $634M.
- Ironwood Pharmaceuticals's current valuation is $1.9B. (January 2022)
- Ironwood Pharmaceuticals has 344 Employees.
- Ironwood Pharmaceuticals grew their employee count by -2% last year.
Ironwood Pharmaceuticals Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Ironwood Pharmaceuticals?
We are building a pharmaceutical company focused on the science & art of great drugmaking. Drugmaking is not a statistical event, or simply a high-throughput industrialized pursuit. Microbia has developed a process for creating and selecting novel drug candidates that integrates the most successful drugmaking practices of the past and the best of today's cutting-edge technologies. Through this innovative discovery process, we are developing medicines that target important human needs. This process has yielded our two clinical programs and a robust preclinical pipeline. We ask the tough questions early. Microbia tackles the most difficult aspects of drugmaking: the interface of pharmacology and chemistry. We require our programs to have a pharmacologically validated mechanism along with robust readouts that are predictive of clinical outcomes. This commitment positions Microbia to rapidly iterate between in vivo models and chemistry to quickly find lead molecules with clinical promise.keywords:N/A
Number of Employees
Employee Growth %
Ironwood Pharmaceuticals News
Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts. We routinely post information that may be important to...
In recent trading, shares of Ironwood Pharmaceuticals Inc (Symbol: IRWD) have crossed above the average analyst 12-month target price of...
$0.31 Earnings Per Share Expected for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) This Quarter. Posted by admin on Apr 11th, 2022.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that its Board of Directors has authorized a new share repurchase program under which the Company may repurchase up to $150 million of its outstanding shares of common stock through December 2022. “I ...
“This agreement represents an attractive opportunity to develop first-in-class products that could help patients with GI diseases reach better outcomes,” Ironwood President Tom McCourt said in a statement. “At Ironwood, we are committed to helping patients with GI diseases and are excited about ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|